Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Raw Materials (2018 - 2024)

Historic Raw Materials for RedHill Biopharma (RDHL) over the last 7 years, with Q4 2024 value amounting to $513000.0.

  • RedHill Biopharma's Raw Materials fell 3804.35% to $513000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $513000.0, marking a year-over-year decrease of 3804.35%. This contributed to the annual value of $513000.0 for FY2024, which is 3804.35% down from last year.
  • Latest data reveals that RedHill Biopharma reported Raw Materials of $513000.0 as of Q4 2024, which was down 3804.35% from $828000.0 recorded in Q4 2023.
  • In the past 5 years, RedHill Biopharma's Raw Materials registered a high of $3.0 million during Q4 2021, and its lowest value of $513000.0 during Q4 2024.
  • In the last 5 years, RedHill Biopharma's Raw Materials had a median value of $1.8 million in 2020 and averaged $1.6 million.
  • In the last 5 years, RedHill Biopharma's Raw Materials surged by 6808.04% in 2021 and then plummeted by 5392.32% in 2023.
  • RedHill Biopharma's Raw Materials (Quarter) stood at $1.8 million in 2020, then soared by 68.08% to $3.0 million in 2021, then plummeted by 40.34% to $1.8 million in 2022, then plummeted by 53.92% to $828000.0 in 2023, then tumbled by 38.04% to $513000.0 in 2024.
  • Its Raw Materials stands at $513000.0 for Q4 2024, versus $828000.0 for Q4 2023 and $1.8 million for Q4 2022.